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Matrix metalloproteinase (MMP)–9 is produced by the central nervous system and inflam-
matory cells in a variety of inflammatory conditions in both animals and humans. MMP-9
promotes inflammation, breakdown of the blood-brain barrier, and vasculitis. Because vas-
culitis is seen frequently in patients with coccidioidal meningitis (CM), this study evaluated
the presence of MMP-9 within the cerebrospinal fluid (CSF) of rabbits infected intracisternally
with Coccidioides immitis arthroconidia. Infected rabbits demonstrated systemic and neuro-
logical sequelae to infection, including CSF pleocytosis. Levels of MMP-9 within CSF were
assayed by use of zymography and compared with MMP-2 levels, which served as an internal
control. Elevated levels of MMP-9 were detectable by day 3, continued to increase through
day 10, and declined by day 15 after infection. MMP-9 may contribute to inflammation and
vasculitis in this animal model. Future work can focus on evaluation of MMP inhibitors, to
gain a better perspective of the role of this MMP in CM.
Matrix metalloproteinases (MMPs) are a family of endopep-
tidases produced by a variety of inflammatory cells [1]. In ad-
dition, MMPs are made by resident brain and vascular cells
during central nervous system (CNS) infection [2]. These enzymes
are thought to have a major role in promoting destructive in-
flammatory processes associated with infection, including dis-
ruption of the blood-brain barrier (BBB), edema formation, and
vascular compromise, with resultant ischemic injury to neural
tissue [2]. MMP-9 appears to play a pivotal role in the patho-
genesis of adverse inflammatory processes, including vasculitis,
as reported for human Streptococcus pneumoniaemeningitis and
corresponding animal models [2–4]. Coccidioidal meningitis is a
highly lethal disease in humans, and vasculitis plays an important
role in its morbidity and lethality, since, despite appropriate ther-
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apy, up to 40% of patients exhibit this complication, as assessed
by computed tomography scanning [5].
We sought to address the pathogenesis of meningeal inflam-
mation and vasculitis by assessing the time course of changes
in MMP-9 levels in cerebrospinal fluid (CSF) in a rabbit model
of Coccidioides immitis–induced meningitis and vasculitis [6].
CSF levels ofMMP-9 have not been addressed either in humans
with coccidioidal meningitis or in an animal model of C. im-
mitis–induced meningitis. In the present study, over a 2-week
period we compared the CSF levels of MMP-9 in rabbits in-
fected intracisternally with C. immitis arthroconidia with levels
in uninfected rabbits that received intracisternal injections of
sterile saline.
Methods
Preparation of C. immitis arthroconidia. Arthroconidia of C. im-
mitis for intracisternal injection were prepared to a final concentration
of arthroconidia/0.25 mL, as described elsewhere [5].43.2 10
Animal inoculation and immunosuppression. Five New Zealand
white male rabbits (Myrtle’s Rabbitry) weighing ∼2.5 kg were anes-
thetized as described elsewhere [5] and received, in a class II biologic
safety cabinet, an intracisternal injection of arthroconi-43.2 10
dia. Five matched control rabbits were injected in a similar fashion
with 0.25 mL of sterile saline. All rabbits were given 2.5 mg/kg
Solu-Cortef (Steris Laboratories) intramuscularly, beginning the
day before infection, the day of infection, and for 3 consecutive
days after infection, as described elsewhere [5].
Postinfection CNS sampling and monitoring. On days 3, 7, 10,
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Figure 1. Representative zymography of cerebrospinal fluid (CSF)
samples from uninfected control rabbits (lanes 1–3) and rabbits with
coccidioidal meningitis (lanes 4–6) 7 days after infection. A gelatinolytic
band of 72 kDa for the released matrix metalloproteinase (MMP)–2 was
present in all samples, and there were no significant differences between
uninfected and infected rabbits. CSF from infected rabbits showed a
marked band at 92 kDa, indicating the presence of MMP-9.
and 15 after infection, animals were anesthetized with isoflurane
gas, and ∼0.25–0.5 mL of CSF was removed by cisternal puncture
under sterile conditions. After white blood cell count analysis by
hemocytometer, the remaining CSF was immediately centrifuged
and frozen at 80C until processed for MMP-9 analysis by elec-
trophoresis and zymography. Rabbits were monitored twice daily
for neurological complications and clinical signs. On day 15, all
rabbits were anesthetized, CSF and blood samples were taken, and
rabbits subsequently were killed with sodium pentobarbital (Eu-
thasol; Delmarva Laboratories) given intravenously. Brains, spinal
cords, and brain basilar arteries of infected and control rabbits
were removed and fixed in 10% neutral buffered formalin for sub-
sequent histologic examination.
Measurement of MMP-2 and MMP-9 levels in CSF. Samples
of CSF (18 mL) were diluted into sample buffer (0.4 M Tris-HCl
[pH 6.8], 10% SDS, 34% glycerol, and 1% bromphenol blue) to a
loading volume of 24 mL and electrophoresed under nonreducing
conditions in 10% polyacrylamide-SDS gels containing type A gel-
atin (1 mg/mL) as proteinase substrate [6]. After electrophoresis
for 2.5 h at 95 V, MMPs were renatured by removal of SDS by
bathing the gel for 1 h in Triton X-100 (2.5% vol/vol). Gels were
then incubated in 10 mM CaCl2, 50 mM Tris, and 50 mM NaCl
(pH 7.65) for 18 h at 37C, to allow proteolysis of the gelatin
substrate, were fixed, and were stained with Coomassie blue. The
gelatinolytic activity of MMP-9 and MMP-2 was determined by
densitometric quantitation of gelatin lysis zones at 92 (MMP-9)
and 72 (MMP-2) kDa, using the Image program (version 1.61;
National Institutes of Health). Infection did not influence the con-
centration of the constitutively produced MMP-2 in CSF of ani-
mals (measured at days 0, 3, 7, 10, and 15), compared with un-
infected control animals. The amount of induced MMP-9 protein
was expressed as a percentage of the amount of MMP-2, which
was used as an internal standard. During electrophoresis, MMPs,
even if present as proenzyme or in the active form but linked to
their natural inhibitors, are activated by partial denaturation in
SDS and/or by autoproteolysis with reconstitution of enzymatic
activity (renaturation) occurring with Triton-X bathing [7]. Hence,
the proteolytic bands for MMP-9 and MMP-2 reflect total levels
of enzymes; however, this may not measure the enzymatic activity
in vivo at that particular moment. Experiments to show the spec-
ificity of the assays for MMP-9 andMMP-2 were done by blocking
these gelatinolytic zones by addition of b-aryl-succinic acid hy-
droxamate [8] and EDTA, 2 agents that specifically block these
MMP enzymes in the incubation buffer (data not shown).
Histologic analysis. Histologic assessment of severity of men-
ingitis was undertaken as described elsewhere [9].
Statistical analysis. Normally distributed variables were pre-
sented as , and differences between groups were com-mean SD
pared with the Mann-Whitney rank sum test.
Results
Clinical, neurological, and histopathological consequences of
C. immitis infection were documented in all infected rabbits. All
infected rabbits, but no control rabbits, demonstrated impair-
ment in mobility, abnormal posture changes (reflecting menin-
gismus), fever up to 40.2C, and weight loss. CSF pleocytosis
was demonstrated in all infected rabbits beginning at day 7,
whereas none of the control rabbits demonstrated pleocytosis.
C. immitis was recovered from the CSF in all infected rabbits
(20 cfu/mm3) beginning at day 7, and significant growth of C.
immitis was also demonstrated from brain (mean, 3.23 log10 cfu/
g) and spinal cord cultures (mean, 2.8 log10 cfu/g).
A representative zymogram, comparing day 7 MMP-9 levels
in infected rabbits with those in control rabbits, is shown in
figure 1. The time course of individual rabbit CSF assessment
of the amount of MMP-9 for a 15-day period after infection
or sham inoculation is presented in figure 2. One infected rabbit
could not be tapped on day 10, and another infected rabbit
met criteria for being killed on day 10 after tapping. Thus, one
data point is missing for day 10, and another is missing for
day 15. In addition, we were unable to tap one control rabbit
on both days 10 and 15. Significant amounts of MMP-9 were
observed on day 3 in the infected group, peaked at days 7 and
10, and slowly decreased thereafter. Low amounts of MMP-9
in control rabbits were observed on day 7, which persisted until
day 15.
Histopathological study of infected rabbits showed evidence
of meningitis of moderate or greater severity in 4 rabbits, with
1 rabbit demonstrating mild meningitis. No meningitis was ob-
served in any of the control rabbits. Vasculitis involving men-
ingeal vessels, brain basilar artery, or both was demonstrated
in 4 rabbits. One rabbit did not demonstrate vasculitis but did
demonstrate elevation of MMP-9 levels. Severity of meningeal
inflammation and the presence of meningeal vasculitis, but not
CSF white blood cell count, appeared to be associated with
higher maximum levels of MMP-9 (table 1).
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Figure 2. Matrix metalloproteinase (MMP)–9 concentration (expressed as a percentage of the constitutively released MMP-2) in cerebrospinal
fluid of rabbits intracisternally infected with Coccidioides immitis () and uninfected control rabbits () over the course of 15 days. A significant
increase in MMP-9 level was first detected at 3 days after infection, reached maximum levels at day 7, and persisted at significantly high levels
until day 10. was considered to be significant.P ! .05
Table 1. Severity of meningitis, presence or absence of meningeal and basilar
artery vasculitis, and maximum cerebrospinal fluid (CSF) white blood cell (WBC)
count, compared with production of matrix metalloproteinase (MMP)–9, in Coc-
cidioides immitis–infected and control rabbits.
Group,
rabbit
Severity of
meningitis
Meningeal
vasculitis
Basilar
artery
vasculitis
Maximum
CSF WBC
count (day)
Maximum MMP-9
concentration (day)a
Infected
152b Moderate   300 (7) 39.58 (7)
153 Severe   1900 (10) 29.81 (10)
154 Severe   1400 (10) 42.14 (10)
155c Mild   1850 (10) 19 (7)
156 Mild-moderate   1550 (10) 17.8 (7)
Control
147d None   0 6.17 (7)
148 None   0 5.58 (15)
149 None   0 9.47 (15)
150 None   0 5.75 (10)
151 None   0 6.35 (15)
NOTE. , Absent; , present.
a Expressed as a percentage of the constitutively released MMP-2.
b Unable to tap at day 10.
c Killed at day 10 after tap.
d Unable to tap at days 10 and 15.
Discussion
Significant increases in MMP-9 levels were observed over a 2-
week period in the 5 C. immitis–infected rabbits that developed
clinical meningitis and vasculitis, compared with sham-treated
control rabbits. We have previously assayed supernatant of the
parasitic-phase, endospore-seeded C. immitis growth medium
through time of endosporulation and did not demonstrateMMP-
9 production by C. immitis (authors’ unpublished data). This
observation is consistent with previous reports implicating in-
flammatory cells and resident brain cells, but not the infectious
agents, as the source of MMP-9 during CNS infection [2, 10].
MMP-9 has been implicated in the disruption of the BBB
during infection, leading to brain edema. This occurs by disrup-
tion of the subendothelial basement membrane via proteolytic
activity that degrades type IV and V collagens [3]. In addition,
MMP-9 is implicated in stimulating the migration of activated
inflammatory cells across the BBB, with resulting further damage
to the barrier by cytokine products of these cells [2, 3]. MMP-9
has also been reported to up-regulate production of tumor ne-
crosis factor (TNF)–a, a major proinflammatory cytokine [2, 3].
TNF-a can, in turn, positively feed back to inflammatory cells,
enhancing their production of MMP-9 and, thus, perpetuating
TNF-a production. In an animal model of pneumococcal men-
ingitis, these events were closely correlated with the severity of
inflammation, including vasculitis, leading to breakdown of vas-
cular integrity, decreased blood flow, and eventual thrombosis of
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vascular lumens. This ultimately leads to focal ischemic and in-
farction sequela. Ampel et al. [11] have demonstrated significant
levels of TNF-a within the CSF of patients with coccidioidal
meningitis.
MMP-9 also appears to play a pivotal role in enhancing
inflammation within the meninges and within the brain paren-
chyma and vascular tree of humans with tuberculous, candidal,
or streptococcal meningitis [3, 12]. In addition, Sorbi et al. [13],
have demonstrated that MMP-9 is associated with the pro-
duction of vasculitis in humans with temporal arteritis. Thus,
MMP-9 activity appears to be a generalized CNS response to
a number of inflammatory conditions.
Our protocol for establishing a rabbit model of coccidioidal
meningitis and vasculitis calls for immunosuppressing rabbits
during the first few days of infection. Immunosuppression could
have affected the temporal events influencing MMP-9 levels
within the CSF of infected animals (i.e., by slowing production)
and may have affected the absolute levels produced. It would
likely not have affected the final interpretation of results, how-
ever, since control animals were also treated with steroids in
exactly the same fashion and had lower levels of MMP-9. The
finding of small amounts of MMP-9 in the control group none-
theless is of interest and could signify the influence of environ-
mental stress factors, anesthesia, and frequent intracisternal
punctures in promoting production of MMP-9, possibly by di-
rect effects on resident CNS cells.
It is of interest that the amount of MMP-9 demonstrated in
this study may promote inflammation and vasculitis in our
model. The increase of MMP-9 in the present rabbit model of
coccidioidal meningitis is slower and less intense but far more
protracted, compared with that in bacterial meningitis [2, 9]
and, to a lesser extent, viral meningitis [1]. Hence, the longi-
tudinal course of MMP-9 up-regulation is in accordance with
the subacute clinical disease.
Our observations here enable the future study of MMP-9 in-
hibitors to assess the role of MMP-9 in promoting meningeal
inflammation and vasculitis. Recently published data [2, 10] dem-
onstrate that 2 inhibitors of MMP-9 (GM6001 and BB1101),
when given intraperitoneally or subcutaneously, respectively, to
rats with experimental S. pneumoniae meningitis, can block the
activity of both MMP-9 and another metalloproteinase, TNF-
a–converting enzyme, which correlated with decreasing severity
of inflammation, an effect that could be used therapeutically in
coccidioidal meningitis. Future studies with our rabbitmodel will
examine the role of endogenous inhibitors of tissue inhibitors of
metalloproteinases and whether other MMPs (such as MMP-8
and MMP-13) are up-regulated in coccidioidal meningitis.
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